US biotech BioAtla has signed a license and option agreement with Pfizer to advance the development and commercialisation of a new class of antibody therapeutics.

These new therapies will be created using BioAtla’s Conditionally Active Biologics platform and Pfizer’s proprietary antibody drug conjugate payloads.